Pharmafile Logo
Pharmafocus logo
Advanced Search
oystein_soug

Targovax announce the appointment of CEO

November 7, 2016

Oystein Soug was announced as the new CEO of Targovax, a clinical stage immuno-oncology company dedicated to the development of …

Appointment
biogen_austria_238

Biogen and Ionis’ spinal muscular atrophy drug meets primary endpoint

November 7, 2016
Manufacturing and Production, Research and Development Biogen, Ionis, spinal muscular atrophy

Biogen and Ionis Pharmaceuticals have released news that their investigational treatment for spinal muscular atrophy (SMA), Spinraza (nusinersen), met the …

News
banner_3

Free Pharmacovigilance Webinar: Just two days left to register!

November 7, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Webinar, pharmacovigilance, primevigilance

There are only two more days to register for our free pharmacovigilance webinar on 10 November, in association with PrimeVigilance. …

News
south_korea_flag

South Korea’s workforce expands 27% in last four years

November 7, 2016
Manufacturing and Production, Sales and Marketing Employment, manufacturing, production, south korea

South Korea’s pharmaceutical workforce has expanded by 27% in the last four years. The growth in jobs is can be …

News
shutterstock_274590824

GSK launches patent infringement action against Pfizer

November 7, 2016
Sales and Marketing Bexsero, trumenba

GlaxoSmithKline has filed a patent infringement lawsuit against rival Pfizer over the alleged copying of its popular meningococcal group B …

News
amgen_hq

FDA approves first therapy for paediatric psoriasis treatment

November 7, 2016
Sales and Marketing Amgen, Enbrel, paediatric, psoriasis

Amgen’s Enbrel has been given approval by the FDA for expanded use to treat children with chronic moderate-to-severe plaque psoriasis. …

News
cmglee_cambridge_cancer_research_web

Cancer Research UK enters new oncology partnership

November 7, 2016
Sales and Marketing Cancer Research UK, TYG Oncology, oncology

Cancer Research UK (CRUK) and its commercial arm, Cancer Research Technology (CRT), haven entered into an agreement with TYG Oncology …

News
nestle_health_sciences

Nestle backs allergy biotech Aimmune to the tune of $145 million

November 7, 2016
Sales and Marketing Aimmune, allergy therapeutics, nestle

Nestle Health Science has invested $145 million in return for a 15% stake in Aimmune Therapeutics. Aimmune pursues food-allergy therapies …

News

Merck KGaA invests €250 million in production in China

November 4, 2016
Manufacturing and Production China, Merck KGaA, Nantong, manufacturing

Merck KGaA inaugurated their Nantong pharmaceutical plant on 4 November. At the same time, Merck also announced that it plans …

News
top_ten_1

Top Ten articles in the pharma industry this week

November 4, 2016
Medical Communications November, news, pharmaceutical, top 10, top ten, top ten stories

This week has seen pharmaceutical companies release their third quarter profits, good news for some whilst others have attempted to …

News
shutterstock_138095450

Sanofi, Lilly & Novo accused of pricing collusion

November 4, 2016
Manufacturing and Production, Medical Communications, Sales and Marketing

Bernie Sanders has continued his assault on pharma pricing after calling out Eli Lilly earlier this week by implicating Lilly, …

News

Lonza grows manufacturing capability by opening further site

November 4, 2016
Medical Communications Lonza, drug product services, manufacturing

Lonza, a Swiss multinational chemical and biotechnology company, has opened a new manufacturing facility in Basel, where their headquarters is …

News
astrazeneca_building_white

AstraZeneca’s post-heart attack drug gets NICE recommendation

November 4, 2016
Medical Communications, Sales and Marketing AstraZeneca, Brillique, NICE, heart attack

AstraZeneca’s Brillique (ticagrelor) has received final recommendation from the National Institute of Health and Care Excellence (NICE) as a prevention …

News

Blood cancer sufferers to receive early access to BMS’ Opdivo

November 3, 2016
Medical Communications Bristol-Myers Squibb, lyphoma, opdivo

Bristol-Myers Squibb has announced that their immunotherapy drug, Opdivo (nivolumab), will be made available to patients in the UK through …

News
clinical_trials

Clinical trials and their patients: The rising costs and how to stem the loss

November 3, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials

The pharmaceutical industry has a big problem and it’s one that keeps getting worse every year – how to stop …

Feature
nice_reception

NICE approves first new drug for breast cancer in a decade

November 3, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

NICE has approved Eisai’s Halaven (eribulin) for routine treatment of sufferers of locally advanced or metastatic breast cancer that has …

News
bernie_2

Lily increases diabetes drug by 700% over 20 years

November 3, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bernie Sanders, Eli Lily, Humalog, diabetes

It has come to light that, over a 20 year period, Eli Lily has increased the price of its diabetes …

News
merck_and_co

MSD’s Alzheimer’s study could break new ground for treatment

November 3, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, MSD, clinical trials

MSD, known as Merck in North America, has published results of a Phase I trial of verubecestat. The drug is …

News
fda2outsideweb

FDA issues warning letter after Chinese firm impedes investigation

November 2, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, FDA

The US Food and Drugs Administration (FDA) has issued a Chinese firm with a warning letter after claims it intentionally …

News
gilead-sciences

Gilead quietly drops drugs from line up alongide Q3 results

November 2, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abzena, Gilead, research and development

Gilead Sciences followed Pfizer in discreetly dropping a drug alongside its third quarter profit reports. The drug in question, for …

News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026